Alakbarzade Vafa, Maduakor Chinedu, Khan Usman, Khandanpour Nader, Rhodes Elizabeth, Pereira Anthony C
Department of Neurology, St George's University Hospitals NHS Foundation Trust, London, UK
Department of Neurology, St George's University Hospitals NHS Foundation Trust, London, UK.
Pract Neurol. 2023 Apr;23(2):131-138. doi: 10.1136/pn-2022-003440. Epub 2022 Sep 19.
Sickle cell disease (SCD) is the most common type of hereditary anaemia and genetic disorder worldwide. Cerebrovascular disease is one of its most devastating complications, with consequent increased morbidity and mortality. Current guidelines suggest that children and adults with SCD who develop acute ischaemic stroke should be transfused without delay. Those with acute ischaemic stroke aged over 18 years who present within 4.5 hours of symptom onset should be considered for intravenous thrombolysis; older patients with conventional vascular risk factors are the most likely to benefit. Endovascular thrombectomy should be considered carefully in adults with SCD as there are few data to guide how the prevalence of cerebral vasculopathy may confound the expected benefits or risks of intervention. We present a practical approach to cerebrovascular disease in sickle cell patients based on the available evidence and our experience.
镰状细胞病(SCD)是全球最常见的遗传性贫血和遗传疾病类型。脑血管疾病是其最具破坏性的并发症之一,会导致发病率和死亡率上升。当前指南建议,患有SCD且发生急性缺血性卒中的儿童和成人应立即接受输血治疗。对于症状发作后4.5小时内就诊的18岁以上急性缺血性卒中患者,应考虑进行静脉溶栓治疗;有传统血管危险因素的老年患者最有可能从中受益。对于患有SCD的成年人,应谨慎考虑血管内血栓切除术,因为几乎没有数据可指导脑血管病变的患病率如何混淆干预的预期益处或风险。我们根据现有证据和我们的经验,提出了一种针对镰状细胞病患者脑血管疾病的实用方法。